Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4360 in CLDN18.2-positive advanced solid tumors
jRCT2031250047Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of AZD4360 in pancreatic adenocarcinoma (PDAC), gastric cancer (GC), esophagogastric junction cancer and 1 more, sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicity incidence, Adverse events and 2 more. Started May 2025; status: active, not recruiting.
02
Drugs
AZD4360
03
Conditions
pancreatic adenocarcinoma (PDAC)gastric cancer (GC)esophagogastric junction cancerbiliary cancer
Beyond the preview
Go deeper on jRCT2031250047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250047.